T. Zbroch

The Esophagogastric Junction / EGJ and GER disease Is salivary prostaglandin E2 output stimulated by esophageal inflammation? T. Zbroch, M. Marcinkiewicz, Z. Namiot, J. Sarosiek (Kansas City)

The Esophagogastric Junction / EGJ and GER disease What is the relation between acid reflux, esophageal glycoconjugate (mucin) secretion, and viscosity? M. Marcinkiewicz, T. Zbroch, Z. Namiot, J. Sarosiek (Kansas City),

The Esophagogastric Junction / EGJ and GER disease What is the role of salivary and esophageal prostaglandin E2 in esophageal protection? J. Sarosiek, M. Marcinkiewicz, T. Zbroch, R.W. McCallum (Kansas City)

Barrett's Esophagus / Etiology and origins of Barrett's epithelium What epidemiological considerations on Barrett's esophagus development can be drawn from salivary epidermal growth factor output? M. Marcinkiewicz, C. Poplawski, T. Zbroch, J. Sarosiek (Kansas City)

Barrett's Esophagus / Diagnosis Can the diminution in heartburn symptomatology be explained by impairment in esophageal glycoconjugate (predominantly mucin) secretion? M. Marcinkiewicz, C. Poplawski, T. Zbroch, Z. Namiot, J. Sarosiek (Kansas City)

Barrett's Esophagus / Markers What is the value of the mucosal content of prostaglandin E2, epidermal growth factor and transforming growth factor a in the surveillance of Barrett's patients? C. Poplawski, M. Marcinkiewicz, T. Zbroch, Z. Namiot, J. Sarosiek (Kansas City)

Barrett's Esophagus / Screening and surveillance What is the significance of persisting salivary epidermal growth factor output impairment in Barrett's patients with endoscopically healed mucosa? C. Poplawski, M. Marcinkiewicz, T. Zbroch, J. Sarosiek (Kansas City)